Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 26, 2011Hepatology

Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYue‐Lei ChenJLJing LvXYXiaolei Ye

Discussion

Loading...

Member takes

Overview

In vitro study demonstrates that sorafenib suppresses TGF-β1-induced transition and apoptosis in mouse hepatocytes, suggesting therapeutic potential for liver fibrosis.

Key Points

  • To determine whether sorafenib can attenuate TGF-β1-induced epithelial-mesenchymal transition and apoptosis in mouse hepatocytes.
  • Treated AML12 cell lines and mouse primary hepatocytes with sorafenib in the presence of TGF-β1.
  • Assessed cellular markers of epithelial-mesenchymal transition, apoptotic activity, and STAT3 phosphorylation.
  • Sorafenib strikingly suppressed TGF-β1-induced epithelial-mesenchymal transition and apoptosis in both AML12 cells and primary hepatocytes.
  • Sorafenib exposure inhibited the phosphorylation of signal transducer and activator of transcription 3 (STAT3) induced by TGF-β1.
  • Sorafenib ameliorated TGF-β1-mediated proapoptotic and profibrotic effects, confirming a protective role in primary liver cells.

Cite This Study

Chen et al. (2011) studied this question.

synapsesocial.com/papers/6a81fd23adfa6baaaee1ffb4https://doi.org/10.1002/hep.24254
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor2021 · 8 citations
  2. 2Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects2024 · 4 citations
  3. 3C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma2026
  4. 4EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage2025
  5. 5Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation2025 · 30 citations